Issels Integrative Immuno-Oncology April 12, 2018  

New Genetic Tests for Early Detection of Pancreatic Cancer

Dear Friend,

Despite advancements in cancer treatment, pancreatic cancer continues to have one of the lower survival rates of all forms. Scientists are encouraged that a new test may increase the effectiveness of early detection and treatment.

Improving Early Detection of Pancreatic Cancer

Medical scans routinely uncover pancreatic cysts, which are small pockets of fluid. While most are benign, some can lead to pancreatic cancer. This poses a dilemma for doctors, who know the importance of early detection but are reluctant to recommend potentially unnecessary surgery.

Dr. Aatur D. Singhi and his team at the University of Pittsburgh Medical Center (UPMC) set out to find a way to test pancreatic cysts before surgery, rather than after. The result was PancreaSeq®, a procedure in which fluid is removed from a cyst and tested for 10 different types of tumor genes.

Breakthroughs in Cancer Testing

The UPMC study is noteworthy for other reasons as well. It was the first to evaluate testing that incorporates next-generation genetic sequencing and the first to be conducted in a certified and accredited clinical laboratory rather than a research facility.

During testing, PancreaSeq® was 100 percent accurate in classifying subjects who had a common precursor to pancreatic cancer. In addition, it also identified cysts that would progress to cancerous lesions with 100 percent accuracy and did not include any false positives.

Issels®: Your #1 Choice for Immunotherapy Cancer Treatment

Gene-targeted therapies are an important part of our non-toxic, integrative cancer treatment programs. Contact us to learn more about cancer vaccines, NK cells and other state-of-the-art therapies at Issels®.

New Genetic Tests for Early Detection of Pancreatic Cancer

Read more interesting articles on the "Issels Cancer Immunotherapy" news/blog posted every Tuesday and Thursday. Check It Out Now »


Synthetic Biomarkers May Aid In Early Detection of Ovarian Cancer

Professor Sangeeta Bhatia and her team at MIT engineered a synthetic biomarker to be approximately 15 times better than a previous version. The nanoparticle was then tested against a blood biomarker in mice with ovarian cancer. The synthetic biomarker was able to detect ovarian cancer composed of tumors as small as two millimeters in diameter.

Get the Full Story!

The Presence of a Molecular Marker May Predict Breast Cancer for Early Treatment

Breast cancer is still the leading cause of death for women who suffer from cancer, but early detection can improve the chances of successful treatment. In 2016 a group of researchers identified a molecular marker that can indicate a woman’s risk for developing the disease. Out of this study group, 69 women later developed cancer and 233 did not. It was discovered that women with a higher percentage of a particular marker were more likely to develop cancer.

Get the Full Story!

Videos – What Do Patients Say About Their Experience?

Watch videos of patients who share their own experiences at the Issels clinics with you. Listen to their stories and cancer journeys.

Get the Full Story!
Interested?

Learn More

Testimonials »

Treatments »

Vaccines »

Statistics »

History »

Locations »

Contact Us »

Connect With Us:


Google +

Contact Info:

Phone: 888-447-7357

Email: info@issels.com



Treatments | Testimonials | Contact Us